SecBot SecBot
PRESS-RELEASE ·Filed Aug 14, 2026

GTBP

GT Biopharma, Inc.
BEARISH
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor for potential dilutive financing given cash runway only through Q4 2026; Phase 1 updates in 2H 2026 could provide catalyst if positive, but near-term funding overhang likely weighs on the stock.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.2960
T+0 close · Aug 14, 2026 · via day close
Latest settled
−41.62%
T+60 · $0.1728
Vs SPY
−38.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $0.2960entry
  2. T+1 · 3mo ago −3.72%α −3.24% · $0.2850
  3. T+5 · 3mo ago −2.50%α −1.13% · $0.2886
  4. T+20 · 2mo ago +3829.05%α +3831.05% · $11.63
  5. T+60 · 8d ago −41.62%α −38.58% · $0.1728
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M is expected to fund operations only through Q4 2026, raising near-term financing concerns. Two Phase 1 TriKE trials are enrolling, with updates expected in 2H 2026.

Key Financial Metrics

EPS
−$0.11
est −$0.08 · -37.5%
Revenue
$0.00
est $0.00 · 0.0%
Rating
miss

Key Facts

  • EPS -$0.11 vs consensus -$0.08 (-37.5% miss)
  • Cash and equivalents $5.1M as of June 30, 2026, sufficient through Q4 2026
  • R&D expenses $1.1M (up from $0.4M YoY), SG&A $3.4M (up from $1.1M YoY)
  • Net loss $4.5M vs $30.2M in prior year (improvement due to non-recurring $28.7M Greenshoe liability in 2025)
  • Phase 1 GTB-3650 (CD33) and GTB-5550 (B7-H3) trials enrolling; updates expected 2H 2026

Financial Impact

EPS miss of 37.5% on a small base; cash burn rate suggests need for financing within ~5 months

epscashoperating expenses

Risk Factors

  • Cash runway limited to Q4 2026, likely requiring additional financing
  • Clinical trial enrollment delays or negative data
  • Potential Nasdaq delisting if stock price remains low

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345280

Track record

12 reports on GTBP

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
  2. Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
  3. Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
  4. Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
  5. Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
  6. Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
  7. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
  8. Aug 14, 202613w ago Press Release Bearish 5/10 Viewing Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
  9. May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
  10. Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026